CYT-387 (momelotinib) is an inhibitor of JAK2 currently under investigation as a potential treatment for myeloproliferative neoplasms; it displays anticancer chemotherapeutic activity. In cellular models of multiple myeloma, momelotinib induces G2/M phase cell cycle arrest. In vivo, this compound decreases tumor burden.
| Cas No. | 1056634-68-4 |
|---|---|
| Purity | ≥98% |
| Formula | C23H22N6O2 |
| Formula Wt. | 414.46 |
| Synonym | CYT387, CYT11387, Momelotinib |
| Solubility | DMSO 74 mg/mL (178.54 mM) Water Insoluble Ethanol Insoluble |
| Appearance | Yellow to light orange powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Abubaker K, Luwor RB, Zhu H, et al. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer. 2014 May 6;14:317. PMID: 24886434.
Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology. 2012 Apr;17 Suppl 1:S129-32. PMID: 22507800.
Monaghan KA, Khong T, Burns CJ, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia. 2011 Dec;25(12):1891-9. PMID: 21788946.
